Sputnik V shows strong safety profile with no hospitalisation cases among elderly: RDIF

master

July 12, 2021

KEY STORY

The Russian Direct Investment Fund (RDIF), an investor of the Russian COVID-19 vaccine Sputnik V, announced on Sunday that the vaccine demonstrated a higher or equal tolerability profile in people above the age of 60 years, during the inoculation campaign in San-Marino.
As per an official release, Sputnik V also showed strong safety with no hospitalisation cases and tolerability among the elderly in the country.
The study was conducted among people in San Marino who received one or two doses of Sputnik V from March 4 to April 8. The results of the study were published in EClinicalMedicine, an open-access clinical journal published by The Lancet.
A descriptive analysis was later conducted to quantify the incidence of adverse events following immunisation on both occasions.
“Our results, albeit preliminary, suggest that Sputnik V has a high tolerability profile in the population aged ≥60 years in terms of short-term AEFIs. This preliminary analysis suggests a higher or equal tolerability profile of the Sputnik V vaccine in the 60+ age group, after both doses, as compared with other widely adopted Covid-19 vaccines,” said the statement.
“Our results also align with the findings of phase 1 and 2 previously conducted studies, then confirmed by phase 3 of the vaccine trial, in terms of overall safety and tolerability. No hospitalisations or deaths were reported. Nearly all reported AEFIs were mild or moderate and/or lasted less than 2 days,” it added.
Sputnik V is among the three COVID-19 vaccines currently being used in India for the nationwide vaccination drive. It was granted an emergency use authorisation in the country in April this year after Covaxin and Covishield.